Osiris Therapeutics 8-K 2014
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2014
OSIRIS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: (443) 545 - 1800
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. Departures of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On February 6, 2014, at a Meeting of the Board of Directors, Frank D. Czworka, Jr. was promoted to serve as the Companys Vice President and General Manager of Wound Care. He reports directly to Lode Debrabandere, President and CEO. No changes have been made to his compensation at this time and Mr. Czworka is not subject to an employment agreement. Mr. Czworka joined Osiris in August 2011as the General Manager of Wound Care and has been responsible for all aspects of Grafix® commercial and clinical development.
Prior to joining Osiris, Mr. Czworka worked for Auxillium Pharmaceuticals from 2009 through July 2011 and from 2000 through 2009 at MedImmune, LLC, both in sales positions. Mr. Czworka is 45-years old and has earned a BSBA degree in Marketing from the University of Central Florida.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.